STOCK TITAN
  1. Home
  2. News
  3. TNXP

Tonix Pharmaceuticals Holding Corp - TNXP STOCK NEWS

Welcome to our dedicated news page for Tonix Pharmaceuticals Holding (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceuticals Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tonix Pharmaceuticals Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tonix Pharmaceuticals Holding's position in the market.

News
Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
clinical trial
-
News
Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Tonix Pharmaceuticals Announces Pricing of $7 Million Public Offering
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. has entered into a securities purchase agreement for the purchase and sale of 7,000,000 shares of its common stock and warrants in a public offering. The gross proceeds of the offering will be approximately $7 million. The company intends to use the net proceeds for working capital, facility build-out, and product acquisition or licensing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.89%
Tags
offering
News
Tonix Pharmaceuticals Announces Proposed Public Offering
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.89%
Tags
offering
-
News
Tonix Pharmaceuticals Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023
Rhea-AI Summary
Tonix Pharmaceuticals announced that development of TNX-4300 (estianeptine) will be prioritized over TNX-601 ER for the treatment of major depressive disorder. Recent findings have shown that estianeptine improves memory and cognition in vivo and restores neuroplasticity in neurons. Tonix intends to accelerate enrollment for the Phase 2 UPLIFT1 trial and expects to report topline data in Q4 2023. They are also accelerating enrollment in the RESILIENT study for TNX-102 SL for fibromyalgia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
earnings clinical trial
-
News
Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Test
Rhea-AI Summary
Tonix Pharmaceuticals announces data supporting the memory- and cognition-enhancing effects of TNX-601 ER and TNX-4300 in Alzheimer's disease and other psychiatric and neurodegenerative conditions. The findings show that tianeptine and estianeptine improve memory and cognition. TNX-601 ER is being tested in a Phase 2 trial for major depressive disorder, with results expected in Q1 2024. TNX-4300 is in preclinical development for mood disorders and neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
none
News
Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
clinical trial
-
News
Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.5%
Tags
clinical trial
-
News
Tonix Pharmaceuticals Comments on Two Long COVID Conferences Sponsored by the U.S. National Academies
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.49%
Tags
covid-19
News
Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
acquisition
Stock TNXP logo
Tonix Pharmaceuticals Holding Corp

Nasdaq:TNXP

TNXP Rankings

#5236 Ranked by Market Cap
#5322 Ranked by Stock Gains
N/A Ranked by Dividends

TNXP Stock Data

15.53M
84.49M
0.01%
19.85%
1.7%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Chatham

About TNXP

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.